87 related articles for article (PubMed ID: 16295141)
1. [Scleroderma-like skin changes following administration of paclitaxel for the treatment of ovarian carcinoma].
Eisenbeilss C; Weizel J; Wolff H
J Dtsch Dermatol Ges; 2003 Jun; 1(6):468-70. PubMed ID: 16295141
[TBL] [Abstract][Full Text] [Related]
2. Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel.
Konishi Y; Sato H; Sato N; Fujimoto T; Fukuda J; Tanaka T
J Obstet Gynaecol Res; 2010 Jun; 36(3):693-6. PubMed ID: 20598060
[TBL] [Abstract][Full Text] [Related]
3. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
De Angelis R; Bugatti L; Cerioni A; Del Medico P; Filosa G
Clin Rheumatol; 2003 Feb; 22(1):49-52. PubMed ID: 12605319
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced scleroderma: a pleiomorphic syndrome.
Alexandrescu DT; Bhagwati NS; Wiernik PH
Clin Exp Dermatol; 2005 Mar; 30(2):141-5. PubMed ID: 15725240
[TBL] [Abstract][Full Text] [Related]
5. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study.
Kupfer I; Balguerie X; Courville P; Chinet P; Joly P
J Am Acad Dermatol; 2003 Feb; 48(2):279-81. PubMed ID: 12582404
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous fibrosis induced by docetaxel: a case report.
Cleveland MG; Ajaikumar BS; Reganti R
Cancer; 2000 Mar; 88(5):1078-81. PubMed ID: 10699898
[TBL] [Abstract][Full Text] [Related]
7. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer.
Dasanu CA; Alexandrescu DT
South Med J; 2008 Nov; 101(11):1161-2. PubMed ID: 19088531
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-related scleredema-like skin changes in a patient with breast cancer.
Tani N; Sugita K; Yamamoto O
Australas J Dermatol; 2018 Aug; 59(3):e215-e217. PubMed ID: 28944958
[No Abstract] [Full Text] [Related]
9. Amyopathic dermatomyositis resembling stasis dermatitis.
Seidler AM; Wasserman DI; González-Serva A; Konnikov N
J Am Acad Dermatol; 2008 Sep; 59(3):515-8. PubMed ID: 18571770
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-induced diffuse scleroderma with possible scleroderma-renal crisis: a case report and literature review of taxanes-induced scleroderma.
Ketpueak T; Chanloung W; Nan KN; Pongsananurak C; Kasitanon N; Louthrenoo W
Clin Rheumatol; 2022 Dec; 41(12):3887-3896. PubMed ID: 36085204
[TBL] [Abstract][Full Text] [Related]
11. [Paclitaxel-induced lupus].
Lortholary A; Cary-Ten Have Dallinga M; El Kouri C; Morineau N; Ramée JF
Presse Med; 2007 Sep; 36(9 Pt 1):1207-8. PubMed ID: 17521858
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
13. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
15. Diffuse Rash After the Administration of Carboplatin and Paclitaxel.
Hazan E; Santa E; Sahu J
Am J Dermatopathol; 2016 May; 38(5):365. PubMed ID: 27097240
[No Abstract] [Full Text] [Related]
16. Diffuse Rash After the Administration of Carboplatin and Paclitaxel: Answer.
Hazan E; Santa E; Sahu J
Am J Dermatopathol; 2016 May; 38(5):393. PubMed ID: 27097241
[No Abstract] [Full Text] [Related]
17. Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients.
Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Kaider A; Leodolter S; Kainz C
Wien Klin Wochenschr; 2000 Dec; 112(23):1007-13. PubMed ID: 11190709
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous fixed drug eruption to paclitaxel; a case report.
Baykal C; Erkek E; Tutar E; Yüce K; Ayhan A
Eur J Gynaecol Oncol; 2000; 21(2):190-1. PubMed ID: 10843484
[TBL] [Abstract][Full Text] [Related]
19. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
